AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 67 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv67
  2. Study completion date: Dec 31, 2025 to Mar 26, 2027v66
  3. 3 versions Re-verified since May 5, 2025, no change to tracked fieldsv63-v65
  4. Study completion date: Dec 31, 2024 to Dec 31, 2025v62
  5. Primary endpoints: 1 to 5v61 Show 4 more changesShow less
    • Secondary endpoints: 1 to 44
    • Study title revised
    • Study arms: 1 to 6
    • Eligibility criteria expanded, about 5 words
Show 43 earlier versionsHide 43 earlier versions
  1. Re-verified, no change to tracked fieldsv60
  2. Study completion date: Dec 29, 2023 to Dec 31, 2024v59
  3. 3 versions Re-verified since Mar 20, 2023, no change to tracked fieldsv56-v58
  4. Study completion date: Dec 30, 2022 to Dec 29, 2023v55
  5. 3 versions Re-verified since Feb 22, 2022, no change to tracked fieldsv52-v54
  6. Study completion date: Dec 31, 2021 to Dec 30, 2022v51
  7. 3 versions Re-verified since Mar 5, 2021, no change to tracked fieldsv48-v50
  8. Study completion date: Dec 31, 2020 to Dec 31, 2021v47
  9. 3 versions Re-verified since Mar 23, 2020, no change to tracked fieldsv44-v46
  10. Study completion date: Dec 31, 2019 to Dec 31, 2020v43
  11. 3 versions Re-verified since Mar 26, 2019, no change to tracked fieldsv40-v42
  12. Study completion date: Dec 31, 2018 to Dec 31, 2019v39
  13. 3 versions Re-verified since Feb 6, 2018, no change to tracked fieldsv36-v38
  14. Study completion date: Dec 29, 2017 to Dec 31, 2018v35
  15. Enrollment target: 64 to 58
    • Site details revised at 4 of 4 sites
    v34
  16. Primary completion date: Jun 2008 to Jun 17, 2008
    • Study completion date: Dec 2017 to Dec 29, 2017
    • Start date: Mar 2007 to Mar 8, 2007
    v33
  17. Study completion date: Dec 2016 to Dec 2017v32
  18. 4 versions Re-verified since Feb 1, 2016, no change to tracked fieldsv28-v31
  19. Study completion date: Dec 2015 to Dec 2016v27
  20. Re-verified, no change to tracked fieldsv26
  21. Study completion date: Mar 2015 to Dec 2015v25
  22. Re-verified, no change to tracked fieldsv24
  23. Study completion date: Dec 2014 to Mar 2015v23
  24. 2 versions Re-verified since Jul 14, 2014, no change to tracked fieldsv21-v22
  25. Study sites: 6 to 4v20
  26. Enrollment target: estimated 90 to confirmed 64
    • Study sites: 5 to 6
    • Study completion date: Feb 2014 to Dec 2014
    v19
  27. Study completion date: Aug 2013 to Feb 2014v18
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
734 trials monitored
See 61 trials at risk
The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies
Trial Details
NCT Number NCT00463814
Lead Sponsor AstraZeneca
Conditions
(from sponsor)		 Tumor, Cancer
Related terms Neoplasms
Enrollment 58 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov